<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35110331</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>81</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of the rheumatic diseases</Title>
          <ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>768</StartPage>
          <EndPage>779</EndPage>
          <MedlinePgn>768-779</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2021-221733</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target &lt;130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level &lt;0.36 mmol/L (&lt;6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases.</AbstractText>
          <CopyrightInformation>© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Drosos</LastName>
            <ForeName>George C</ForeName>
            <Initials>GC</Initials>
            <Identifier Source="ORCID">0000-0001-7987-9588</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Vedder</LastName>
            <ForeName>Daisy</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-1715-9555</Identifier>
            <AffiliationInfo>
              <Affiliation>Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Houben</LastName>
            <ForeName>Eline</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boekel</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0001-5473-7786</Identifier>
            <AffiliationInfo>
              <Affiliation>Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atzeni</LastName>
            <ForeName>Fabiola</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Rheumatology Unit, Department of Internal Medicine, University of Messina, Messina, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Badreh</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>EULAR Patient Research Partner, Brussels, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boumpas</LastName>
            <ForeName>Dimitrios T</ForeName>
            <Initials>DT</Initials>
            <Identifier Source="ORCID">0000-0002-9812-4671</Identifier>
            <AffiliationInfo>
              <Affiliation>4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brodin</LastName>
            <ForeName>Nina</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedics, Danderyd Hospital Corp, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bruce</LastName>
            <ForeName>Ian N</ForeName>
            <Initials>IN</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>González-Gay</LastName>
            <ForeName>Miguel Ángel</ForeName>
            <Initials>MÁ</Initials>
            <Identifier Source="ORCID">0000-0002-7924-7406</Identifier>
            <AffiliationInfo>
              <Affiliation>Rheumatology Division, Hospital Universitario Marqués de Valdecilla and University of Cantabria, Santander, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacobsen</LastName>
            <ForeName>Søren</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5654-4993</Identifier>
            <AffiliationInfo>
              <Affiliation>Copenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kerekes</LastName>
            <ForeName>György</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Department of Medicine, University of Debrecen, Debrecen, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchiori</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>EULAR Patient Research Partner, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mukhtyar</LastName>
            <ForeName>Chetan</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-9771-6667</Identifier>
            <AffiliationInfo>
              <Affiliation>Rheumatology Department, Norfolk and Norwich University Hospital, Colney Lane, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramos-Casals</LastName>
            <ForeName>Manuel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sattar</LastName>
            <ForeName>Naveed</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreiber</LastName>
            <ForeName>Karen</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>EMEUNET member, Danish Hospital for Rheumatic Diseases, Sonderburg, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sciascia</LastName>
            <ForeName>Savino</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-1266-9441</Identifier>
            <AffiliationInfo>
              <Affiliation>EMEUNET member, CMID-Nephrology, San Giovanni Bosco Hospital, University of Torino, Torino, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Svenungsson</LastName>
            <ForeName>Elisabet</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-3396-3244</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Rheumatology Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szekanecz</LastName>
            <ForeName>Zoltan</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-7794-6844</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University of Debrecen Faculty of Medicine, Debrecen, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tausche</LastName>
            <ForeName>Anne-Kathrin</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University Clinic Carl Gustav Carus at the TU Dresden, Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyndall</LastName>
            <ForeName>Alan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, University of Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Halm</LastName>
            <ForeName>Vokko</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Amsterdam University Medical Center, location VU University medical center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voskuyl</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Macfarlane</LastName>
            <ForeName>Gary J</ForeName>
            <Initials>GJ</Initials>
            <Identifier Source="ORCID">0000-0003-2322-3314</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, NHS Grampian, Aberdeen, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ward</LastName>
            <ForeName>Michael M</ForeName>
            <Initials>MM</Initials>
            <Identifier Source="ORCID">0000-0003-1857-9367</Identifier>
            <AffiliationInfo>
              <Affiliation>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Nurmohamed</LastName>
            <ForeName>Michael T</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Amsterdam University Medical Center, location VU University Medical Centre, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tektonidou</LastName>
            <ForeName>Maria G</ForeName>
            <Initials>MG</Initials>
            <Identifier Source="ORCID">0000-0003-2238-0975</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece mtektonidou@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Ann Rheum Dis</MedlineTA>
        <NlmUniqueID>0372355</NlmUniqueID>
        <ISSNLinking>0003-4967</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>268B43MJ25</RegistryNumber>
          <NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006073" MajorTopicYN="Y">Gout</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008947" MajorTopicYN="Y">Mixed Connective Tissue Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009140" MajorTopicYN="Y">Musculoskeletal Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword>
        <Keyword MajorTopicYN="N">autoimmune diseases</Keyword>
        <Keyword MajorTopicYN="N">cardiovascular diseases</Keyword>
        <Keyword MajorTopicYN="N">lupus erythematosus</Keyword>
        <Keyword MajorTopicYN="N">systemic</Keyword>
        <Keyword MajorTopicYN="N">systemic vasculitis</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: GCD, DV, EH, LB, SB, DTB, NB, GK, FM, CM, MR-C, KS, SS, VPvH, GJM, MMW and MN have nothing to declare. FA: research grants from BMS, Celgene, Novartis and Sandoz and consulting fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer and Sanofi-Aventis, all unrelated to this manuscript; INB: grant from GSK paid to institution, consulting fees from Astra Zeneca, GSK, Eli lilly, UC, MSD paid to institution, support for attending meetings and/or travel from GSK, participation on a data safety monitoring board/or advisory board from Aurinia, Astra Zeneca and ILTOO paid to institution, all unrelated to this manuscript; MÁG-G: grants/research support from AbbVie, MSD, Jansen and Roche paid to institution and personal consulting fees/participation in company sponsored speakers bureau from AbbVie, Pfizer, Roche, Celgene, MSD, Novartis, SOBI and Sanofi, all unrelated to this manuscript; SJ: grants from BMS paid to institution, personal consulting fees from Astra Zeneca, and personal fees from Danish Medicolegal Council, all unrelated to this manuscript; NS: grants paid to institution from Astrazeneca, Boehringer Ingelheim and Roche Diagnostics, personal consulting fees from Afimmune, Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Hanmi Pharamceuticals, MSD, Novartis, Novo Nordisk, Pfizer and Sanofi, all unrelated to this manuscript; ES: grant from Merck and honoraria from Janssen, all unrelated to this manuscript; ZS: research grants from Pfizer paid to institution and personal consulting fees from Pfizer, MSD, Lilly, Novartis, Roche, Gedeon Richter, Boehringer Ingelheim, Abbvie, all unrelated to this manuscript; A-KT: speakers fee from Berlin Chemie Menarini, Novarti and personal fees and non-financial support from AstraZeneca and Grünenthal, all unrelated to this manuscript; AT: consulting fees from Magenta Therapeutics and personal fees from Novartis and Idorsia for participation on a Data Safety Monitoring Board or Advisory Board, all unrelated to this manuscript; AV: personal consulting fees from Astra Zeneca and GS, all unrelated to this manuscript; MGT: research grants from Genesis, GSK, MSD, Pfizer and UCB paid to institution, and personal consulting fees from Genesis, GSK and Novartis, all unrelated to this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35110331</ArticleId>
        <ArticleId IdType="doi">10.1136/annrheumdis-2021-221733</ArticleId>
        <ArticleId IdType="pii">annrheumdis-2021-221733</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
